Mydecine Submits Pre-Investigational New Drug Briefing Package to the FDA for MYCO-001 Seamless Phase 2/3 Smoking… Feb 1, 2022
Mydecine To Supply Lead Drug Candidate, MYCO-001, for Multi-Site NIDA Grant-Funded Smoking Cessation Study Lead by Dr.… Oct 5, 2021
Changing The Public’s View On Psychedelic Therapeutics With Mydecine Innovation’s Dr. Jetly Oct 1, 2021
Mydecine Innovations Group Announces MYCO-001 Seamless Phase 2/3 Smoking Cessation Clinical Trial Sep 7, 2021
